Stryker boosts 2025 outlook with 17.3% increase in medical surgery and neurotechnology unit

Stryker has revised its profit forecast for 2025, raising it to between 9.5% and 10%, up from the initial estimate of 8.5%-9.5%, as a result of strong growth in its medical surgery and neurotechnology segment. The Michigan-based company reported profits of $6 billion in Q2 2025, an increase of 11.1% from $5.4 billion in Q2 2024. Stryker now anticipates an adjusted profit range of $13.40 to $13.60 per share for the full year 2025.

The company’s financial results revealed a total sales figure of $3.7 billion in its medical surgery and neurotechnology business unit, marking a notable 17.3% increase from Q2 2024. Within this segment, the medical category achieved total sales of $990 million, reflecting a 9% growth from its performance of $908 million in Q2 2024. However, the vascular segment emerged as the primary sales driver, experiencing a significant 52.3% surge to $498 million compared to $327 million in Q2 2024.

This surge can be attributed to Stryker’s acquisition of peripheral vascular specialist Inari Medical for $4.9 billion in February 2025. This strategic move has positioned Stryker to compete with established market players such as Boston Scientific and Terumo. The acquisition of Inari augments Stryker’s neurotechnology portfolio with the addition of the FlowTriever System for pulmonary embolism treatment and the ClotTriever System for peripheral vessel thrombectomy.

Analysts at GlobalData predict that the global peripheral vascular devices market is on track for a compound annual growth rate (CAGR) of 4.6% and is set to achieve a valuation of approximately $18.3 billion by 2034, representing a substantial increase from $11.7 billion in 2024. With the prevalence of peripheral artery diseases like deep vein thrombosis and pulmonary embolism on the rise globally, Stryker’s acquisition of Inari positions it to strengthen its standing in the cardiovascular device market.

In other sectors of the business, Stryker’s orthopaedics unit saw sales of $2.2 billion in Q2 2025, registering a modest 2% uptick from Q2 2024. The trauma and extremities division experienced the most significant growth, climbing 15% to reach $957 million, up from $832 million in Q2 2024. This growth indicates that Stryker’s $5.4 billion acquisition of upper extremities specialist Wright Medical in 2019 continues to yield positive results.

Reflecting on the company’s Q2 2025 performance, Kevin A Lobo, Stryker’s chairman and CEO, emphasized, “Our strong sales and earnings reflect demand for our products, our robust innovation pipeline, and ongoing operational excellence.”